Regis Technologies Expands Its GMP-Approved Chiral Separations Services with SFC

January 15, 2007

Regis Technologies, Inc. partners with pharmaceutical, biotechnology, and other companies to help expedite drugs to market by providing synthesis and separations services. Regis Technologies announced today it has added Supercritical Fluid Chromatography (SFC) to its separations services and will offer GMP separations April 1, 2007.

Regis Technologies, Inc. partners with pharmaceutical, biotechnology, and other companies to help expedite drugs to market by providing synthesis and separations services. Regis Technologies announced today it has added Supercritical Fluid Chromatography (SFC) to its separations services and will offer GMP separations April 1, 2007.

The new service marries SFC with the company?s proven expertise chiral HPLC services and products. Regis Technologies has long fulfilled the analytical and preparative market needs with its quality chromatography products including their proprietary Chiral Stationary Phases. Being a fully compliant GMP organization since 1993, Regis will now offer SFC as a GMP stand-alone service or in concert with its GMP manufacturing.

Regis Technologies will use the Thar SFC Method Station equipment with Regis and other chiral stationary phases, and have agreed to be a host demonstration partner for Thar systems. Regis chose the Thar system for its quality, service, and ability to validate ancillary systems.

?We are pleased to add SFC to our chiral separations services,? says Sean F. Bradley, Regis Technologies Director of Business Development . ?SFC is well-established as a method-of-choice for chiral separations. It enjoys advantages over traditional preparative HPLC separations such as shorter run times, less solvent consumption and less waste without sacrificing purity.? Potential pharmaceutical organizations that may benefit from this offering are: preclinical laboratories in need of small amounts of enantiomerically pure compounds, pharmaceutical companies producing phase I, II and III clinical candidates requiring enantiomeric separation, and labs isolating impurities. Regis Technologies continues to improve and grow. In its third expansion in less than seven years, Regis has expanded its non-GMP development area to include 7,000 additional square feet of synthetic labs and offices.